Showing posts with label crizotinib. Show all posts
Showing posts with label crizotinib. Show all posts
Wednesday, January 27, 2021

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

›
In continuation of my update on lorlatinib  and   crizotinib                                                                   lorlatinib   ...
Friday, July 29, 2016

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

›
In continuation of my update on  crizotinib The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients...
Tuesday, February 9, 2016

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

›
The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-smal...
Monday, June 15, 2015

Existing drugs could help prevent deadly familial stomach and lobular breast cancers

›
Deadly familial stomach and lobular breast cancers could be successfully treated at their earliest stages, or even prevented, by existing ...
Friday, January 9, 2015

New targeted therapy shows promise in patients with ALK-positive advanced NSCLC

›
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular ...
Thursday, September 20, 2012

Scientists develop new strategy to overcome drug-resistant childhood cancer

›
Researchers at The Institute of Cancer Research in London have found a way to overcome the resistance of cancer cells to a drug called cri...
Thursday, June 28, 2012

Experimental Drug Helps Fight Some Childhood Cancers, Study Finds

›
In continuation of my update on Crizotinib Experimental Drug Helps Fight Some Childhood Cancers, Study Finds :  A new targeted drug ther...
Saturday, August 20, 2011

EMA has accepted Pfizer's regulatory submissions for review of two investigational compounds crizotinib and bosutinib

›
European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds  crizotinib,...
Wednesday, June 23, 2010

Crizotinib Shows Dramatic Results for Shrinking Tumors (lung cancer)....

›
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. Th...